Compare IIF & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IIF | CHRS |
|---|---|---|
| Founded | 1993 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.5M | 209.8M |
| IPO Year | N/A | 2014 |
| Metric | IIF | CHRS |
|---|---|---|
| Price | $22.95 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.51 |
| AVG Volume (30 Days) | 33.3K | ★ 700.5K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 13.94% | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $73.08 |
| Revenue Next Year | N/A | $30.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.83 | $0.81 |
| 52 Week High | $27.99 | $2.62 |
| Indicator | IIF | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 57.41 | 45.98 |
| Support Level | $22.01 | $1.38 |
| Resistance Level | $23.66 | $1.74 |
| Average True Range (ATR) | 0.42 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 73.11 | 47.63 |
Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.